Marrow graft rejection by repeated transfusions of allogeneic donor spleen cells

Bone Marrow Transplantation

Volumn 40, Issue 7, 2007, Pages 691-698

  Xu, L H ^a   Fang, J P ^a   Huang, W G ^a   Xu, H G ^a   Weng, W J ^a   Kao, G S ^b   Le, Y ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BLOOD SMEAR; CELL MEDIATED CYTOTOXICITY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FLUORESCENCE MICROSCOPY; FROZEN SECTION; GRAFT REJECTION; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION; SPLEEN CELL; SURVIVAL RATE; SURVIVAL TIME; TRANSFUSION; TREATMENT FAILURE;

ANIMALS; BONE MARROW TRANSPLANTATION; CELL TRANSPLANTATION; GRAFT REJECTION; HUMANS; ISOANTIBODIES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MODELS, ANIMAL; SPLEEN; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 34648846033     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705791     Document Type: Article

References (26)

1. Schrier SL, Angelucci E. New strategies in the treatment of the thalassemias. Annu Rev Med 2005; 56: 157-171.
2. Krishnamurti L, Abel S, Maiers M, Flesch S. Availability of unrelated donors for hematopoietic stem cell transplantation for hemoglobinopathies. Bone Marrow Transplant 2003; 31: 547-550.
3. Jaime-Perez JC, Riuz-Arguelles GJ, Gomez-Almaguer D. Haematopoietic stem cell transplantation to treat aplastic anaemia. Expert Opin Biol Ther 2005; 5: 617-626.
4. Kaminski ER, Hows JM, Goldman JM, Batchelor JR. Pretransfused patients with severe aplastic anaemia exhibit high numbers of cytotoxic T lymphocyte precursors probably directed at non-HLA antigens. Br J Haematol 1990; 76: 401-405.
5. Fang J, Huang S, Chen C, Zhou D, Li CK, Li Y et al. Umbilical cord blood transplantation in Chinese children with beta-thalassemia. J. Pediatr Hematol Oncol 2004; 26: 185-189.
6. Gluckman E, Gluckman JC, Andersen E, Devergie A, Dausset J. Lymphocytotoxic antibodies and bone marrow grafts from HLA-identical siblings. I. HLA antibodies. Transplantation 1978; 26: 284-286.
7. Friedman DF, Lukas MB, Jawad A, Larson PJ, Ohene-Frempong K, Manno CS. Alloimmunization to platelets in heavily transfused patients with sickle cell disease. Blood 1996; 88: 3216-3222.
8. Lo SC, Chang JS, Lin SW, Lin DT. Platelet alloimmunization after long-term red cell transfusion in transfusion-dependent thalassemia patients. Transfusion 2005; 45: 761-765.
9. Braun WE. Laboratory and clinical management of the highly sensitized organ transplant recipient. Hum Immunol 1999; 26: 245-260.
10. Terasaki PI, Cai J. Humoral theory of transplantation: Further evidence. Curr Opin Immunol 2005; 17: 541-545.
11. Tambur AR, Pamboukian SV, Costanzo MR, Heirrera ND, Dunlap S, Montpetit M et al. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation 2005; 80: 1019-1025.
12. Hadjiliadis D, Chaparro C, Reinsmoen NL, Gutierrez C, Singer LG, Steele MP et al. Pre-transplant panel reactive antibody in lung transplant recipients is associated with significantly worse post-transplant survival in a multicenter study. J Heart Lung Transplant 2005; 24: S249-S254.
13. Cai J, Terasaki PI. Humoral theory of transplantation: Mechanism, prevention, and treatment. Hum Immunol 2005; 66: 334-342.
14. Xu H, Chilton PM, Tanner MK, Huang Y, Schanie CL, Dy-Liacco M et al. Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients. Blood 2006; 108: 3611-3619.
15. Gale RP, Fitchen JH, Cahan M, Opelz G, Cline MJ. Pretransplant lymphocytotoxins and bone-marrow graft rejection. Lancet 1978; 1: 170-172.
16. Gluckman E. Pretransplant lymphocytotoxins and bone-marrow graft rejection. Lancet 1978; 1: 443.
17. Warren RP, Storb R, Weiden PL, Su PJ, Thomas ED. Prediction of marrow graft rejection by the lymphocyte-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity assays. Transplantation 1980; 30: 118-121.
18. Altermann WW, Seliger B, Sel S, Wendt D, Schlaf G. Comparison of the established standard complement-dependent cytotoxicity and flow cytometric crossmatch assays with a novel ELISA-based HLA crossmatch procedure. Histol Histopathol 2006; 21: 1115-1124.
19. Marcusson-Stahl M, Cederbrant K. A flow-cytometric NK-cytotoxicity assay adapted for use in rat repeated dose toxicity studies. Toxicology 2003; 193: 269-279.
20. Colson YL, Schuchert MJ, Ildstad ST. The abrogation of allosensitization following the induction of mixed allogeneic chimerism. J Immunol 2000; 165: 637-644.
21. Taylor PA, Ehrhardt MJ, Roforth MM, Swedin JM, Panoskaltsis-Mortari A, Serody JS et al. Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood 2007; 109: 1307-1315.
22. Semple JW, Speck ER, Milev YP, Blanchette V, Freedman J. Indirect allorecognition of platelets by T helper cells during platelet transfusions correlates with anti-major histocompatibility complex antibody and cytotoxic T lymphocyte formation. Blood 1995; 86 805-812.
23. Tomita Y, Yoshikawa M, Zhang QW, Shimizu I, Okano S, Iwai T et al. Induction of permanent mixed chimerism and skin allograft tolerance across fully MHC-mismatched barriers by the additional myelosuppressive treatments in mice primed with allogeneic spleen cells followed by cyplophosphamide. J Immunol 2000; 165: 34-41.
24. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood 2005; 106: 1901-1910.
25. Travlos GS. Histopathology of bone marrow. Toxicol Pathol 2006; 34: 566-598.
26. Nagata S, Okano S, Yonemitsu Y, Nakagawa K, Tomita Y, Yoshikai Y et al. Critical roles of memory T cells and antidonor immunoglobulin in rejection of allogeneic bone marrow cells in sensitized recipient mice. Transplantation 2006; 82: 689-698.